Daftar pustaka

Agnihotri, S.A., Mallikarjuna, N.N., Aminabhavi, T.M., 2004. Recent advances on chitosan-based micro- and nanoparticles in drug delivery B. *J. Control. Release* 100: 5–28.

Anwar, S.., S.J, H., Aryandono, T., Haryana, S.M., 2017. micro-RNA : biogenesis, fungsi, dan perannya dalam proses karsinogenesis dan penatalaksanaan kanker. Gadjah Mada University Press, Yogyakarta.

Bajan, S., Hutvagner, G., 2020. RNA-Based Therapeutics : From Antisense Oligonucleotides to miRNAs. *Cells* 137: 1–27.

Balogh, J., Victor III, D., Gordon, S., Li, X., Ghobrial, R.M., Monsour Jr, P.H., 2016. Hepatocellular carcinoma : a review. *J. Hepatocell. Carcinoma* 3: 41–53.

Beg, M.S., Brenner, A.J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., et.al., 2017b. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Invest New Drugs* 35(2): 180–188.

Calvisi, D.F., Ladu, S., Gorden, A., Farina, M., Conner, E.A., Lee, J.U.S., et.al., 2006. Ubiquitous Activation of. *Gastroenterology* 130: 1117–1128.

Carballal-santos, B., Aaldering, L.J., Ritzefeld, M., Pereira, S., Sewald, N., Moerschbacher, M.., 2015. Physicochemical and biological characterization of chitosan- microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Nat. Publ. Gr.* 5: 1–15.

Chiao, P.J., Ling, J., 2011. Kras , Pten , NF-kB , and inflammation : Dangerous Liaisons. *Cancer Discov.* 1: 103–106.

Cho, C.W., 2012. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. *Expert Opin. Ther. Targets* 16: 747–759.

Chou, C., Shrestha, S., Yang, C., Chang, N., 2018. miRTarBase update 2018 : a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.* 46: 296–302.

Chow, P.K.H., Gandhi, M., Tan, S., Khin, M.W., Khasbazar, A., Ong, J., et.al., 2020. SIRveNIB : Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. *J. Clin. Oncol.* 36: 1913-1921.

COM, J., I, H., As, S., Ra, G., CRA, L., J, K., 2019. Risk Factors for Hepatocellular Carcinoma and Its Mortality Rate : A Multicenter Study in Indonesia Abstract. *Arch. Cancer Res.* 7 (1): 1–7.

Csaba, N., Köping-höggård, M., Alonso, M.J., 2009. Ionically crosslinked chitosan / tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. *Int. J. Pharm.* 382: 205–214.

D, L., SW, C., MJ, F., BB, K., 2009. Hep G2 is a hepatoblastoma-derived cell line. *Hum. Pathol.* 40(10): 1512–1515.

Dhiman, G., Srivastava, N., Goyal, M., Rakha, E., Khaiboullina, S.F., Rizvanov, A.A., Baranwal, M., 2019. Metadherin : A Therapeutic Target in Multiple Cancers. *Front. Oncol.* 9: 1–8.

Dietrich, P., Freese, K., Mahli, A., Thasler, W.E., 2018. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “ dual-hit ” option. *Oncotarget* 9: 3605–3618.

Dietrich, P., Koch, A., Fritz, V., Hartmann, A., Bosserhoff, A.K., Hellerbrand, C., 2017. Wild type Kirsten rat sarcoma is a novel microRNA- 622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. *Gut* 67: 1328–1341.

Dizaj, S.M., Jafari, S., Khosroushahi, A.Y., 2014. A sight on the current nanoparticle-based gene delivery vectors. *Nanoscale Res. Lett.* 9: 1–9.

Dutta, R., Mahato, R.I., 2017. Recent Advances in Hepatocellular Carcinoma Therapy. *Pharmacol. Ther.* 173: 106–117.

Emdad, L., Das, S.., Hu, B., 2016. AEG-1 / MTDH / LYRIC : A Promiscuous Protein Partner Critical in Cancer , Obesity , and CNS Diseases, Advances in Cancer Research.

Fan, R., Chen, P., Zhao, D., 2011. Cooperation of deregulated Notch signaling and Ras pathway in human hepatocarcinogenesis. *J. Mol. Histol.* 42: 473–481.

Forner, A., Reig, M., Bruix, J., 2018. Hepatocellular carcinoma. *Lancet* 391: 1301–1314.

Freier, T., Shan, H., Kazazian, K., Shoichet, M.S., 2005. Controlling cell adhesion and degradation of chitosan films by N -acetylation. *Biomaterials* 26: 5872–5878.

Gao, W., Lu, Y., Wang, F., Sun, J., Bian, J., Wu, H., 2019. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5. *Eur. Rev. Med. Pharmacol. Sci.* 23: 7874–7883.

Gao, Z., Zhang, L., Sun, Y., 2012. Nanotechnology applied to overcome tumor drug resistance. *J. Control. Release* 162: 45–55.

Gaur, S., Wen, Y., Song, J.H., Parikh, N.U., Lingegowda, S., Shi, Y., et.al., 2015. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget* 6: 29161–29177.

Ghadi, A., 2014. Synthesis and optimization of chitosan nanoparticles: Potential applications in nanomedicine and biomedical engineering. *Casp. J. Int. Med.* 5: 156–161.

Grammatikakis, I., Gorospe, M., Abdelmohsen, K., 2013. Modulation of Cancer Traits by Tumor Suppressor microRNAs. *Int. J. Mol. Sci.* 14: 1822–1842.

Hagemann, T., Lawrence, T., Mcneish, I., Charles, K.A., Kulbe, H., Thompson, R.G., et.al., 2008. macrophages by targeting NF-kB. *J. Exp. Med.* 205: 1261–1268.

He, R., Yang, L., Lin, Xiaomiao, Chen, X., Lin, Xinggu, Wei, F., Liang, X., Wu, Y., et.al., 2015. MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. *Int. J. Clin. Exp. Pathol.* 8: 15632–15641.

Huan, L., Liang, L., He, X., 2016. Role of microRNAs in inflammation-associated liver cancer. *Cancer Biol. Med.* 13: 408–424.

Huang, M., Fong, C., Khor, E., Lim, L., 2005. Transfection efficiency of chitosan vectors : Effect of polymer molecular weight and degree of deacetylation. *J. Control. Release* 106: 391–406.

Huang, S., He, X., 2011. The role of microRNAs in liver cancer progression. *Br. J. Cancer* 104: 235–240.

Jin'en, W., Juntao, D., Jing, Y., Xiaola, G., Yadong, Z., 2018. MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer. *Front. Immunol.* 9: 546–555.

Jisha, K.D.M.S., 2017. Chitosan nanoparticles preparation and applications. *Environ. Chem. Lett.*

Jun, L., Yang, G., Zhisu, L., 2019. Biomedicine & Pharmacotherapy The utility of serum exosomal microRNAs in hepatocellular carcinoma. *Biomed. Pharmacother.* 111: 1221–1227.

Jung, H. Il, Ahn, T., Bae, S.H., Chung, J.C., Kim, H., Chin, S., Jeong, D., 2015. Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma : an independent prognostic factor. *Ann. Surg. Treat. Res. Astrocyte* 88: 77–85.

Kaban, K., Salva, E., Akbuga, J., 2016. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. *Nucleic Acid Ther.* 1–11.

Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., 2019. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections : A Review. *Int. J. Mol. Sci.* 20.

Karimi, M., Avci, P., Ahi, M., Gazori, T., Hamblin, R.M., 2016. Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p- shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study. *J. Nanopharmaceutical Drug Deliv.* 1: 266–278.

Karin, M., Greten, F.R., 2005. NF-κB: linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* 5: 749–759.

Karmakar, S., Kaushik, G., Nimmakayala, R., Rachagani, S., 2019. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. *Semin. Cancer Biol.* 54: 63–71.

Katas, H., Alpar, H.O., 2006. Development and characterisation of chitosan nanoparticles for siRNA delivery. *J. Control. Release* 115: 216–225.

Khan, A.Q., Kuttikrishnan, S., Siveen, K.S., Prabhu, K.S., Shanmugakonar, M., Naemi, H.A.A.-, Haris, M.,et.al., 2019. RAS-mediated oncogenic signaling pathways in human malignancies. *Semin. Cancer Biol.* 54: 1–13.

Kim, M., Slack, F.J., 2014. MicroRNA-mediated regulation of KRAS in cancer. *J. Hematol. Oncol. 2014* 7: 1–4.

Lam, J.K.W., Chow, M.Y.T., Zhang, Y., Leung, S.W.S., 2015. siRNA Versus miRNA as Therapeutics for Gene Silencing. *Mol. Ther. Nucleic Acids* 4: 1–20.

Li, Q., Wang, M., Wang, N., Wang, J., Qi, L., Mao, P., 2018. Biomedicine & Pharmacotherapy Downregulation of microRNA-216b contributes to glioma cell growth and migration by promoting AEG-1-mediated signaling. *Biomed. Pharmacother.* 104: 420–426.

Li, Wen-fang, Dai, H., Ou, Q., Zuo, G., Liu, C., 2015a. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH / PTEN / AKT pathway. *Tumor Biol.*

Li, Wen-fang, Ou, Q., Dai, H., Liu, C., 2015b. Lentiviral-Mediated Short Hairpin RNA Knockdown of MTDH Inhibits Cell Growth and Induces Apoptosis by Regulating the PTEN / AKT Pathway in Hepatocellular Carcinoma. *Int. J. Mol. Sci.* 16: 19419–19432.

Li, Weijia, Zhou, J., Xu, Y., 2015. Study of the in vitro cytotoxicity testing of medical devices (Review). *Biomed. Reports* 3: 617–620.

Liu, T., Zhang, L., Joo, D., Sun, S., 2017. NF-κB signaling in inflammation. *Signal Transduct. Target. Ther.* 2.

Luck, M.E., Muljo, S.A., Collins, C.B., Alerts, E., 2015. Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases. *J. Immunol.* 194: 5047–5052.

Maliawan, R.P., Veronica, S., Putu, N., Pande, A., Dewi, A., Wisnu, P., et.al., 2018. miRNA-124 loaded chitosan as novel therapy to induce neuroprotective and neurogenesis for improving brain revitalization after ischemic stroke. *Bali Med. J.* 7: 361–368.

Mancino, A., Lawrence, T., 2019. NF κ B and tumor-associated macrophages. *Clin. Cancer Res.* 16: 784–789.

Meng, X., Zhu, D., Yang, S., Wang, X., Xiong, Z., Zhang, Y., et.al., 2012. Cytoplasmic Metadherin (MTDH) Provides Survival. *J. Biol. Chem.* 287: 4485–4491.

Mickey, B., Park, S., Zhao, D., Hatanpaa, K.J., Mickey, B.E., Saha, D., et.al., 2009. RIP1 activates PI3K-Akt via a dual mechanism involving NF- κ B-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down- regulation of PTEN RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF- K B – Mediated Inhibition of the mTOR-S6. *Cancer Res.* 69. d

Mohammed, M.A., Syeda, J.T.M., Wasan, K.M., Wasan, E.K., 2017. An Overview of

Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. *Pharmaceutics* 9: 1–26.

Nguyen, D.D., Chang, S., 2018. Development of novel therapeutic agents by inhibition of oncogenic microRNAs. *Int. J. Mol. Sci.* 19: 1–17.

Nussinov, R., Tsai, C., Jang, H., 2019. Seminars in Cancer Biology Is Nanoclustering essential for all oncogenic KRas pathways ? Can it explain why wild-type KRas can inhibit its oncogenic variant ? *Semin. Cancer Biol.* 54: 114–120.

Palomba, G., Colombino, M., Contu, A., Massidda, B., Baldino, G., Pazzola, A., et.al., 2012. Prevalence of KRAS , BRAF , and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population : clues from Sardinia. *J. Transl. Med.* 10: 1.

Parikh, N.D., 2019. Treatment for Advanced Hepatocellular Carcinoma : Current Standard and the Future. *Clin. Liver Dis.* 13.

Pawar, A., Prabhu, P., 2019. Nanosoldiers : A promising strategy to combat triple negative breast cancer. *Biomed. Pharmacother.* 110: 319–341.

Pereira, D.M., Rodrigues, P.M., Borralho, P.M., Rodrigues, C.M.P., 2013. Delivering the promise of miRNA cancer therapeutics. *Drug Discov. Today* 18: 282–289.

Piasecka, D., Braun, M., Kordek, R., Sadej, R., Romanska, H., 2018. MicroRNAs in regulation of triple-negative breast cancer progression. *J. Cancer Res. Clin. Oncol.* 144: 1401–1411.

Rai, V., Abdo, J., Alsuwaidan, A.N., Agrawal, S., 2018. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. *Mol. Cell. Biochem.* 437: 13–36.

Rampino, A., Borgogna, M., Blasi, P., Bellich, B., Cesàro, A., 2013. Chitosan nanoparticles : Preparation , size evolution and stability. *Int. J. Pharm.* 455: 219–228.

Reid, G., Kao, S.C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., et.al., 2016. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. *Epigenomics* 8: 1079–1085.

Rennie, W., Kanoria, S., Liu, C., Mallick, B., Long, D., Wolenc, A., et.al., 2016b.

STarMirDB : A database of microRNA binding sites. *RNA Biol.* 13: 554–560.

Robertson, C.L., Srivastava, J., Rajasekaran, D., Gredler, R., Akiel, M.A., Jariwala, N., et.al., 2015. The role of AEG-1 in the development of liver cancer. *Hepatology* 2: 303–312.

Rupaimoole, R., Slack, F.J., 2017. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* 16: 203–221.

Santos-carballal, B., 2018. Chitosan in Non-Viral Gene Delivery : Role of Structure , Characterization Methods , and Insights in Cancer and Rare Diseases Therapies. *Polymers (Basel).* 10: 1–51.

Serna-blasco, R., Sanz-álvarez, M., Aguilera, Ó., García-foncillas, J., 2019. Targeting the RAS-dependent chemoresistance : The Warburg connection. *Semin. Cancer Biol.* 54: 80–90.

Shi, L., Middleton, J., Jeon, Y., Magee, P., Veneziano, D., Laganà, A., et.al., 2018. KRAS induces lung tumorigenesis through microRNAs modulation. *Cell Death Dis.*

Sia, D., Villanueva, A., Friedman, S.L., Llovet, J.M., 2017. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. *Gastroenterology* 152: 745–761.

Sidhu, K., Kapoor, N.R., Pandey, V., Kumar, V., 2015. The " macro " world of microRNAs in hepatocellular carcinoma. *Front. Oncol.* 5: 1–8.

Simanshu, D.K., Nissley, D. V, Mccormick, F., 2017. RAS Proteins and Their Regulators in Human Disease. *Cell* 170: 17–33.

Srdic-rajic, T., Zuvela, M., 2017. Targeted therapy and personalized medicine in hepatocellular carcinoma : drug resistance , mechanisms , and treatment strategies. *J. Hepatocell. Carcinoma* 4: 93–103.

Stotz, M., Gerger, A., Haybaeck, J., Kiesslich, T., Bullock, M.D., Pichler, M., 2015. Molecular Targeted Therapies in Hepatocellular Carcinoma : Past , Present and Future. *Anticancer Res.* 5744: 5737–5744.

Tang, J., Ahmad, A., Sarkar, F.H., 2012. The Role of MicroRNAs in Breast Cancer Migration , Invasion and Metastasis. *Int. J. Mol. Sci.* 12: 13414–13437.

Thillai, K., Ross, P., Sarker, D., Thillai, K., Ross, P., Sarker, D., 2016. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis ? *Wold J. Gastrointest. Oncol.* 8: 173–185.

Vasudevan, K.M., Gurumurthy, S., Rangnekar, V.M., 2004. Suppression of PTEN Expression by NF- kB Prevents Apoptosis. *Mol. Cell. Biol.* 24: 1007–1021.

Villanueva, A., 2019. Hepatocellular Carcinoma. *N. Engl. J. Med.* 380: 1450–1462.

Visalli, M., Bartolotta, M., Polito, F., Oteri, R., Barbera, A., Arrigo, R., et.al., 2018. miRNA expression profiling regulates necroptotic cell death in hepatocellular carcinoma. *Int. J. Oncol.* 53: 771–780.

Waller, L.P., Deshpande, V., Pyrsopoulos, N., Waller, L.P., Deshpande, V., Pyrsopoulos, N., 2015. Hepatocellular carcinoma : A comprehensive review. *World J. Gastroenterol.* 7: 2648–2663.

Wang, L., Yue, Y., Wang, X., Jin, H., 2015. Function and clinical potential of microRNAs in hepatocellular carcinoma (Review). *Oncol. Lett.* 10: 3345–3353.

Wang, T., Larcher, M.L., Ma, L., Veedu, N.R., 2018. Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection. *Molecules* 23: 1–15.

Xu, W., Deng, B., Lin, P., Liu, C., Li, B., Huang, Q., et.al., 2019. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. *Sci. China Life Sci.* 62: 1–14.

Xu, X., Tao, Y., Shan, L., Chen, R., Jiang, H., Qian, Z., et.al., 2018. The Role of MicroRNAs in Hepatocellular Carcinoma. *J. Cancer* 9: 3557–3569.

Yan, C., Huo, X., Wang, S., Feng, Y., Gong, Z., 2015. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. *J. Hepatol.* 63: 420–428.

Yang, C., Yin, M., Xu, G., Lin, W., Chen, J., Zhang, Y., 2019. Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma. *Adv. Healthc. Mater.* 8 (8).

Yang, F., Zhang, W., Shen, Y.A.N., Guan, X., 2015. Identification of dysregulated microRNAs in triple-negative breast cancer (Review). *Int. J. Oncol.* 46: 927–932.

Yang, L., Tian, Y., Leong, W.S., Song, H., Yang, W., Wang, M., et.al., 2018. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro. *Breast Cancer Res.* 20: 1–13.

Ye, H., Zhang, C., Wang, B., Tan, X., Zhang, W., Teng, Y., et.al., 2014. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. *Oncogene* 33: 5133–5138.

Yin, Z., Ren, W., 2019. MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin. *Onco. Targets. Ther.* 12: 759–771.

Yoo, B.K., Emdad, L., Su, Z., Villanueva, A., Chiang, D.Y., Mukhopadhyay, N.D., et.al., 2009. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. *J. Clin. Invest.* 119: 465–477.

Yoon, S.M., Ryoo, B.-Y., Lee, S.J., Kim, J.H., Shin, J.H., An, J.H., et.al., 2018. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. *JAMA Oncol.* 4: 661–669.

Ysrafil, 2019. Efek Sitotoksisitas Sediaan Nanopartikel Kitosan Berbasis MikroRNA Terhadap Kultur Sel Line Kanker Ovarium SCOV3.

Zhang, H., Zhao, X., Liu, S., Li, J., Wen, Z., Li, M., 2010. Molecular and Cellular Endocrinology 17 NL E 2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkB-dependent pathway. *Mol. Cell. Endocrinol.* 317: 31–43.

Zhang, M., Li, M., Li, N., Zhang, Z., Liu, N., 2017. miR-217 suppresses proliferation , migration , and invasion promoting apoptosis via targeting MTDH in hepatocellular carcinoma. *Oncol. Rep.* 37: 1772–1778.

Zhao, W., Yu, S., Lu, Z., Ma, Y., Gu, Y., Ã, J.C., 2010. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. *Carcinogenesis* 31: 1726–1733.

Zhou, K., Luo, X., Wang, Y., Cao, D., Sun, G., 2017. MicroRNA-30a suppresses tumor progression by blocking Ras / Raf / MEK / ERK signaling pathway in hepatocellular carcinoma. *Biomed. Pharmacother.* 93: 1025–1032.

Zhou, Z., Deng, H., Yan, W., Huang, H., Deng, Y., 2012. Expression of Metadherin / AEG-1 Gene Is Positively Related to Orientation Chemotaxis and Adhesion of Human Hepatocellular Carcinoma Cell Lines of Different Metastatic Potentials *. *J. Huazong Univ. Sci. Technol.* 32: 353–357.

Zhu, H.D., Liao, J.Z., He, X.X., Li, P.Y., 2015. The emerging role of astrocyte-elevated gene-1 in hepatocellular carcinoma (Review). *Oncol. Rep.* 34: 539–546.

Zhu, X., Sun, H., 2019. Emerging agents and regimens for hepatocellular carcinoma. *J. Hematol. Oncol.* 12: 1–10.